<DOC>
	<DOCNO>NCT02427295</DOCNO>
	<brief_summary>Long-term ( 3 year ) clinical hormonal outcome acromegalic patient treat surgery without long act somatostatin analogue .</brief_summary>
	<brief_title>Hormonal Outcomes Acromegalic Patients With Treated Surgery With Without Long Acting Somatostatin Analogues</brief_title>
	<detailed_description>Patients diagnose acromegaly GH-secreting pituitary adenoma receive TSA Asan Medical Center ( Seoul , Korea ) Aug 2013 Aug 2015 recruit . The eligible patient population consist 30 adult , male female patient Age 18 older . - Number patient treatment group : Surgical treatment = 15 , Surgery medical treatment = 15 - Number Centers : 1 ( single center )</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Age 18 old . 2 . Patients diagnose acromegaly GHsecreting pituitary adenoma sellar MRI , meet biochemical criterion outline ( refer 1 . Diagnosis acromegaly ) typical acromegalic feature . 3 . No prior use somatostatin analogue . 4 . Adequate hepatic renal function 5 . Provision sign write informed consent 1 . Severe comorbid illness untreatable malignancy and/or active infection . 2 . Pregnant lactate woman 3 . Hypersensitivity Sandostatin component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>